Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the pace of U.S. pump shipments and the near-term impact of the company’s business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the U.S. CEO John Sheridan emphasized that the company’s ability to drive operational efficiencies and expand access to its technology contributed to improved margins and a more favorable product mix.
Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).
Tandem Diabetes (TNDM) Q2 CY2026 Highlights:
- Revenue: $254.6 million vs analyst estimates of $253.8 million (5.8% year-on-year growth, in line)
- Adjusted EPS: -$0.31 vs analyst estimates of -$0.32 (in line)
- Adjusted EBITDA: $6.42 million vs analyst estimates of $3.52 million (2.5% margin, 82.2% beat)
- The company reconfirmed its revenue guidance for the full year of $1.08 billion at the midpoint
- Operating Margin: -5.4%, up from -21.5% in the same quarter last year
- Market Capitalization: $1.63 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Tandem Diabetes’s Q2 Earnings Call
- Matthew Blackman (TD Cowen) asked about progress and challenges with the pharmacy transition. CEO John Sheridan said the rollout was tracking as planned, with no major surprises and ongoing efficiency improvements.
- Richard Newitter (Truist Securities) inquired about type 2 diabetes retention trends. Sheridan replied that type 2 attrition remained only modestly higher than type 1 and stable, emphasizing focused outreach and upcoming CMS policy changes.
- Larry Biegelsen (Wells Fargo) questioned the need for stronger U.S. pump growth in the second half. CFO Leigh Vosseller cited building momentum from new products and pharmacy adoption as key drivers.
- Anna Filipe (Piper Sandler) probed the rationale for maintaining gross margin guidance despite a strong Q2. Vosseller explained that pharmacy channel adoption dynamics, particularly pumps outpacing supplies, would create temporary margin variability.
- Joanne Karen Wuensch (Citi) followed up on Mobi tubeless FDA progress. Sheridan confirmed the filing occurred in Q2 and that a scaled launch was planned for the second half of the year, pending clearance.
Catalysts in Upcoming Quarters
In the coming quarters, our team will focus on (1) the pace of pharmacy channel adoption and its impact on recurring revenue, (2) the FDA clearance and market introduction of Mobi tubeless and related infusion set technologies, and (3) stabilization of supply chain dynamics as new products come online. Progress on type 2 diabetes segment penetration and international direct market launches will also be important markers for sustained growth.
Tandem Diabetes currently trades at $23.24, up from $18.79 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
